Rallybio reports results from epidemiological analysis evaluating FNAIT risk
PremiumThe FlyRallybio reports results from epidemiological analysis evaluating FNAIT risk
3M ago
Rallybio downgraded to Neutral from Overweight at JPMorgan
Premium
The Fly
Rallybio downgraded to Neutral from Overweight at JPMorgan
4M ago
Rallybio files to sell 3.64M shares of common stock for holders
Premium
The Fly
Rallybio files to sell 3.64M shares of common stock for holders
4M ago
Rallybio price target lowered to $9 from $12 at H.C. Wainwright
PremiumThe FlyRallybio price target lowered to $9 from $12 at H.C. Wainwright
6M ago
Rallybio reports Q4 EPS (50c), consensus (46c)
Premium
The Fly
Rallybio reports Q4 EPS (50c), consensus (46c)
6M ago
Rallybio price target lowered to $13 from $14 at Wedbush
Premium
The Fly
Rallybio price target lowered to $13 from $14 at Wedbush
8M ago
Rallybio announces 45% reduction in workforce
PremiumThe FlyRallybio announces 45% reduction in workforce
8M ago
Rallybio to begin RLYB212 study in 2H, cash runway extended into Q3
Premium
The Fly
Rallybio to begin RLYB212 study in 2H, cash runway extended into Q3
9M ago
Rallybio price target lowered to $15 from $18 at Evercore ISI
Premium
The Fly
Rallybio price target lowered to $15 from $18 at Evercore ISI
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100